Paper
2 April 1996 Influence of drug and light regimens in determining PDT efficacy with lutetium texaphyrin
Kathryn W. Woodburn, Stuart W. Young M.D., Richard A. Miller
Author Affiliations +
Abstract
Lutetium texaphyrin (PCI-0123) is a pure, stabile, water-soluble photosensitizer with a broad absorption band centered at 732 nm. Lutetium texaphyrin has shown considerable promise in the treatment of murine mammary tumors. PDT requires the coexistence of a photosensitizer, oxygen and light. Light fluences, rates and delivery methods have a profound influence on oxygen depletion and re-equilibration and therefore tumor responsiveness. The effect of different photoirradiation and sensitizer dose in eradicating/retarding EMT6 tumors in BALB/c mice using lutetium texaphyrin was evaluated. An increase in light fluences increased efficacy. No difference was observed between a continuous versus a fractionated light protocol. A reduction in time between sensitizer injection and laser treatment enhanced tumor treatment.
© (1996) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Kathryn W. Woodburn, Stuart W. Young M.D., and Richard A. Miller "Influence of drug and light regimens in determining PDT efficacy with lutetium texaphyrin", Proc. SPIE 2675, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy V, (2 April 1996); https://doi.org/10.1117/12.237535
Lens.org Logo
CITATIONS
Cited by 9 scholarly publications.
Advertisement
Advertisement
RIGHTS & PERMISSIONS
Get copyright permission  Get copyright permission on Copyright Marketplace
KEYWORDS
Tumors

Photodynamic therapy

Lutetium

Oxygen

Absorption

Laser therapeutics

Statistical analysis

Back to Top